X

Week in Review: The Latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer September 11, 2015

Week in Review: The Latest from PhRMA.

Share This

week-in-reviewMedicines in Development: According to the latest Medicines In Development report, America’s biopharmaceutical research companies are currently developing 836 medicines and vaccines to treat various cancers. Learn more about this promising pipeline here.

Biopharmaceutical Patents: The patent system is critical to achieving research and development breakthroughs, treatments and cures. Check out a new infographic for 5 reasons why biopharmaceutical patents are different than those in other industries.

340B Discounts: This week’s 340B Spotlight features a new infographic that explains how 340B discounts work to facilitate patient access to prescription medicines. Check it out here.

Medicaid Adherence Yields Savings: A new study co-authored by PhRMA and published in the latest edition of Health Affairs found that improved adherence by Medicaid beneficiaries can reduce U.S. medical costs by reducing expensive hospitalizations and emergency room visits. Find out more here.

Value at the Crossroads: Frameworks and tools that seek to assess the value of certain treatment options are gaining increased attention. Learn more about the significant implications these tools hold and the importance of ensuring informed decision-making by patients and health care providers remains intact.

Medicare Monday: Take a look at this week’s post for resources for understanding Medicare Part B and D.

Topics: Medicines in Development, Research and Development